SLC22A31

Across TCGA pan-cancer cohorts, SLC22A31 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC22A31 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SLC22A31 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC22A31 expression acts as an unfavorable survival marker.

CESC, MESO, and SARC are the cancer types where SLC22A31 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.146	0.740	<.001	12	view →
MESO	DFS	Median	All	0.099	0.392	.030	9	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC22A31–CESC (DFS)

Open the CESC breakdown →